Your browser doesn't support javascript.
The landscape of mRNA nanomedicine.
Huang, Xiangang; Kong, Na; Zhang, Xingcai; Cao, Yihai; Langer, Robert; Tao, Wei.
  • Huang X; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kong N; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Zhang X; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Cao Y; School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
  • Langer R; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. yihai.cao@ki.se.
  • Tao W; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
Nat Med ; 28(11): 2273-2287, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2116990
ABSTRACT
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanomedicine / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-02061-1

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanomedicine / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-02061-1